Barclays’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-37,000
| Closed | -$5.78M | – | 5362 |
|
|
2020
Q4 | $5.78M | Hold |
37,000
| – | – | ﹤0.01% | 1435 |
|
|
2020
Q3 | $4.23M | Sell |
37,000
-100
| -0.3% | -$10.8K | ﹤0.01% | 1505 |
|
|
2020
Q2 | $4.16M | Sell |
37,100
-116,300
| -76% | -$12.3M | ﹤0.01% | 1511 |
|
|
2020
Q1 | $13.8M | Buy |
153,400
+39,500
| +35% | +$3.88M | 0.01% | 827 |
|
|
2019
Q4 | $12.3M | Sell |
113,900
-60,100
| -35% | -$6.43M | 0.01% | 1247 |
|
|
2019
Q3 | $17M | Buy |
174,000
+135,700
| +354% | +$15.3M | 0.01% | 974 |
|
|
2019
Q2 | $5.02M | Sell |
38,300
-32,700
| -46% | -$4.21M | ﹤0.01% | 1861 |
|
|
2019
Q1 | $9.6M | Sell |
71,000
-58,900
| -45% | -$7.32M | 0.01% | 1249 |
|
|
2018
Q4 | $12.6M | Buy |
129,900
+49,900
| +62% | +$5.9M | 0.01% | 1015 |
|
|
2018
Q3 | $11.1M | Sell |
80,000
-61,200
| -43% | -$7.68M | 0.01% | 1199 |
|
|
2018
Q2 | $17.5M | Sell |
141,200
-242,900
| -63% | -$28.4M | 0.02% | 858 |
|
|
2018
Q1 | $42.8M | Sell |
384,100
-126,600
| -25% | -$15.1M | 0.03% | 480 |
|
|
2017
Q4 | $61.1M | Buy |
510,700
+193,000
| +61% | +$23.5M | 0.05% | 324 |
|
|
2017
Q3 | $44.6M | Sell |
317,700
-132,500
| -29% | -$18M | 0.05% | 333 |
|
|
2017
Q2 | $54.8M | Buy |
450,200
+368,300
| +450% | +$42.9M | 0.06% | 253 |
|
|
2017
Q1 | $9.93M | Sell |
81,900
-128,600
| -61% | -$16.6M | 0.01% | 876 |
|
|
2016
Q4 | $25.8M | Buy |
210,500
+181,400
| +623% | +$22.2M | 0.03% | 490 |
|
|
2016
Q3 | $3.57M | Sell |
29,100
-60,800
| -68% | -$7.83M | ﹤0.01% | 1547 |
|
|
2016
Q2 | $10.5M | Buy |
89,900
+73,400
| +445% | +$10.4M | 0.01% | 816 |
|
|
2016
Q1 | $2.29M | Sell |
16,500
-38,800
| -70% | -$5.7M | ﹤0.01% | 1799 |
|
|
2015
Q4 | $10.5M | Sell |
55,300
-13,100
| -19% | -$2.29M | 0.01% | 862 |
|
|
2015
Q3 | $10.7M | Sell |
68,400
-101,400
| -60% | -$18.5M | 0.01% | 898 |
|
|
2015
Q2 | $30.6M | Buy |
169,800
+114,900
| +209% | +$19.8M | 0.03% | 459 |
|
|
2015
Q1 | $9.5M | Buy |
54,900
+7,300
| +15% | +$1.32M | 0.01% | 1105 |
|
|
2014
Q4 | $8.81M | Sell |
47,600
-18,300
| -28% | -$3.39M | 0.01% | 1274 |
|
|
2014
Q3 | $10.9M | Buy |
65,900
+3,200
| +5% | +$526K | 0.01% | 1116 |
|
|
2014
Q2 | $9.78M | Sell |
62,700
-112,100
| -64% | -$17.7M | 0.01% | 1177 |
|
|
2014
Q1 | $26.6M | Sell |
174,800
-52,100
| -23% | -$8.28M | 0.03% | 552 |
|
|
2013
Q4 | $30M | Sell |
226,900
-176,100
| -44% | -$21.1M | 0.03% | 549 |
|
|
2013
Q3 | $46.7M | Buy |
403,000
+141,000
| +54% | +$15.5M | 0.06% | 315 |
|
|
2013
Q2 | $24.2M | Buy |
+262,000
| New | +$25.2M | 0.03% | 559 |
|
Other funds holding ALXN
Barclays's ALXN Position: Q4 2021 in Review
Barclays sold out of Alexion Pharmaceuticals (ALXN) in Q4 2021, closing a stake of 6 shares — an estimated $22K sold.
Barclays first reported a position in ALXN in Q2 2013 and held it in 34 quarters. The position peaked at $547M in Q1 2021. 2 funds tracked by Wall St. Rank hold ALXN as of Q4 2021.
- Barclays reported no remaining Alexion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Barclays sold 6 Alexion Pharmaceuticals shares in Q4 2021, an estimated $22K.
- Barclays first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 34 quarters.
- Barclays's Alexion Pharmaceuticals position peaked at $547M in Q1 2021.
- 2 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2021.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.